Login

Cancer Genetics

OncoMap90 – Comprehensive Profiling for Blood Cancers

90 Genes for Hematologic Malignancies

Precision Medicine for Leukemia and Blood Disorders.

A 90-gene panel designed for myeloid cancers like AML, MDS, and MPN, giving oncologists critical insight into prognosis, targeted therapies, and trial options.

Order Test
Talk to a Genetic Counselor

What is the OncoMap90 Test?

OncoMap90 profiles mutations across 90 genes in myeloid malignancies. These genetic changes influence treatment decisions, risk classification, and eligibility for new therapies.

Who benefits most from this test:

  • Patients with past drug side effects
  • People on multiple medications
  • Those starting treatment for heart disease, depression, cancer, or chronic pain
  • Providers managing complex cases

Why This Test Matters

For Patients & Families

  • Identify inherited cancer risks early.

  • Take preventive steps such as enhanced screening or lifestyle changes.

  • Share results with relatives for family‑wide health planning.

For Providers

  • Improve patient care with genetic insights.

  • Guide referrals, screening protocols, and preventive interventions.

  • Support cascade testing for at‑risk family members.

For Proactive Consumers

  • Even without a family history, you may carry mutations that increase cancer risk.

  • Knowledge empowers you to take control of your health.

Cancer types covered

Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes (MDS)

Myeloproliferative Neoplasms (MPN)

Chronic Myelomonocytic Leukemia (CMML)

Other hematologic cancers

Other solid tumors

 Key genes covered

Common drivers

FLT3, NPM1, DNMT3A, IDH1, IDH2, TET2, ASXL1, RUNX1, TP53, CEBPA

 Other relevant

KIT, KRAS, NRAS, JAK2, CALR, MPL, SF3B1, SRSF2

Melanoma

Ovarian and Endometrial Cancers

Thyroid and Gastric Cancers

Other solid tumors

SEE FULL GENE LIST
ABL1, ARID1A, ASXL1, ATM, ATRX, B2M, BARD1, BCL2, BCL6, BCOR, BCORL1, BRAF, BRCA1, BRCA2, BRIP1, BTK, CALR, CARD11, CBL, CBLB, CBLC, CD79B, CDKN2A, CEBPA, CHEK1, CHEK2, CREBBP, CSF3R, DNMT3A, EGFR, ERBB2, ETV6, EZH2, FANCL, FBXW7, FGFR3, FLT3, GATA1, GATA2, GNA13, GNAS, GNB1, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KMT2A, KMT2D, KRAS, MET, MPL, MTOR, MYC, MYD88, NF1, NOTCH1, NPM1, NRAS, PALB2, PDGFRA, PHF6, PIK3CA, PIM1, PPM1D, PTEN, PTPN11, RAD21, RAD51B, RAD51C, RAD51D, RET, RHOA, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SOCS1, SRSF2, STAG2, STAT3, STAT5B, TET2, TNFAIP3, TP53, U2AF1, WT1, XPO1, ZRSR2

What you will learn from this test

  • Mutations driving your blood cancer
  • Prognostic information for risk stratification
  • Targeted therapy options, including targeted inhibitors
  • Trial eligibility based on mutation profile

Why choose this OncoMap90?

  • Comprehensive 90-gene panel for blood cancers
  • Actionable insights for therapy and prognosis
  • Clinical-grade reporting for hematologists
  • Supports precision medicine approaches in blood cancers

How it works

Test ordered through your oncologist or provider

Provide a bone marrow aspirate or blood sample

Receive a secure report with therapy guidance

Pricing

Order Your OncoMap90 Test Today

For Solid tumors consider the OncoMap50 (50 genes)

OncoMap90 Test

₦855,000

(For Provider)

Order Test

OncoMap90 Test

₦900,000

(Direct-to-Consumer)

Order Test